- Home
- DVAX vs HASI Comparison
DVAX vs HASI Comparison
Compare DVAX & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- HASI
- Stock Information
- Founded
- DVAX 1996
- HASI 1981
- Country
- DVAX United States
- HASI United States
- Employees
- DVAX N/A
- HASI N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- HASI Real Estate Investment Trusts
- Sector
- DVAX Health Care
- HASI Real Estate
- Exchange
- DVAX Nasdaq
- HASI Nasdaq
- Market Cap
- DVAX 1.3B
- HASI 3.5B
- IPO Year
- DVAX 2004
- HASI 2013
- Fundamental
- Price
- DVAX $9.65
- HASI $28.35
- Analyst Decision
- DVAX Buy
- HASI Strong Buy
- Analyst Count
- DVAX 4
- HASI 6
- Target Price
- DVAX $26.50
- HASI $37.67
- AVG Volume (30 Days)
- DVAX 1.9M
- HASI 822.0K
- Earning Date
- DVAX 11-06-2025
- HASI 11-06-2025
- Dividend Yield
- DVAX N/A
- HASI 5.97%
- EPS Growth
- DVAX N/A
- HASI N/A
- EPS
- DVAX N/A
- HASI 1.59
- Revenue
- DVAX $316,268,000.00
- HASI $92,418,000.00
- Revenue This Year
- DVAX $23.23
- HASI $184.19
- Revenue Next Year
- DVAX $16.57
- HASI $13.31
- P/E Ratio
- DVAX N/A
- HASI $17.72
- Revenue Growth
- DVAX 26.66
- HASI N/A
- 52 Week Low
- DVAX $9.20
- HASI $21.98
- 52 Week High
- DVAX $14.63
- HASI $36.56
- Technical
- Relative Strength Index (RSI)
- DVAX 40.56
- HASI 56.77
- Support Level
- DVAX $9.20
- HASI $27.61
- Resistance Level
- DVAX $9.94
- HASI $28.53
- Average True Range (ATR)
- DVAX 0.30
- HASI 0.56
- MACD
- DVAX -0.03
- HASI -0.01
- Stochastic Oscillator
- DVAX 37.93
- HASI 57.33
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.